Known targets — ChEMBL curated mechanism
DHFRGARTPTGFRPTGIRPTGS1PTGS2TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8envmurAthyA
The experimentally established mechanism targets of Tromethamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tromethamine SCHEMBL342628 | 0.87 | MEN1 (0.71) | MEN1LMNAKMT2A | |
| Tromethamine SCHEMBL845321 | 0.80 | MEN1 (0.53) | MEN1LMNAKMT2A | |
| Tromethamine SCHEMBL10701087 | 0.80 | MEN1 (0.46) | MEN1LMNAKMT2A | |
| Tromethamine SCHEMBL7193959 | 0.79 | MEN1 (0.83) | MEN1LMNAKMT2A | |
| Tromethamine SCHEMBL28216031 | 0.79 | MEN1 (0.83) | MEN1LMNAKMT2A | |
| Tromethamine SCHEMBL975 | 0.79 | — | — | |
| Tromethamine SCHEMBL17484 | 0.79 | MEN1 (1.00) | MEN1LMNAKMT2A | |
| Tromethamine SCHEMBL3696191 | 0.79 | — | — | |
| Tromethamine SCHEMBL6653331 | 0.76 | MEN1 (0.77) | MEN1LMNAKMT2A | |
| Tromethamine SCHEMBL9644059 | 0.76 | MEN1 (0.77) | MEN1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025217430-A1 | HETEROCYCLIC COMPOUNDS AS NRAS INHIBITORS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-10-16 | — | — | WO | disclosed |
| US-11339185-B2 | Cyclic dinucleotides as anticancer agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-05-24 | — | — | US | disclosed |
| EP-3981806-A1 | HIGH REFRACTIVE INDEX MATERIALS | Rohm and Haas Electronic Materials LLC (US) | 2022-04-13 | — | — | EP | disclosed |
| EP-3752516-B1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2022-02-23 | — | — | EP | disclosed |
| EP-3954681-A1 | SPIROHEPTANE SALICYLAMIDES AND RELATED COMPOUNDS AS INHIBITORS OF ROCK | Bristol-Myers Squibb Company (US) | 2022-02-16 | — | — | EP | disclosed |
| EP-3402790-B1 | SPIROHEPTANE SALICYLAMIDES AND RELATED COMPOUNDS AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2021-10-06 | — | — | EP | disclosed |
| EP-3752516-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | Bristol-Myers Squibb Company (US) | 2020-12-23 | — | — | EP | disclosed |
| US-10829501-B2 | Spiroheptane salicylamides and related compounds as inhibitors of ROCK | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-11-10 | — | — | US | disclosed |
| US-20200131200-A1 | SPIROHEPTANE SALICYLAMIDES AND RELATED COMPOUNDS AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2020-04-30 | — | — | US | disclosed |
| US-10611776-B2 | Spiroheptane salicylamides and related compounds as inhibitors of rock | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-04-07 | — | — | US | disclosed |
| WO-2011044501-A9 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2012-04-19 | — | — | WO | disclosed |
| WO-2011044503-A9 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2012-02-09 | — | — | WO | disclosed |
| WO-2011044503-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2011-04-14 | — | — | WO | disclosed |
| WO-2011044501-A2 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2011-04-14 | — | — | WO | disclosed |
| US-20090123198-A1 | INTERMEDIATE TRANSFER MEMBER, METHOD OF PRODUCING INTERMEDIATE TRANSFER MEMBER, AND IMAGE FORMING APPARATUS PROVIDED WITH INTERMEDIATE TRANSFER MEMBER | KONICA MINOLTA BUSINESS TECHNOLOGIES, INC. (JP) | 2009-05-14 | — | — | US | disclosed |
| EP-0886637-A4 | — | — | 1998-12-30 | — | — | EP | disclosed |
| EP-0886637-A1 | INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-12-30 | — | — | EP | disclosed |
| EP-0573122-B1 | Polymers containing repeating cycloketonic units, and method for obtaining them | CONSIGLIO NAZIONALE RICERCHE (IT) | 1998-08-19 | — | — | EP | disclosed |
| US-5369187-A | Polymerizing a conjugated diene with carbon monoxide | CONSIGLIO NAZIONALE DELLE RICERCHE (IT) | 1994-11-29 | — | — | US | disclosed |
| EP-0573122-A1 | Polymers containing repeating cycloketonic units, and method for obtaining them | CONSIGLIO NAZIONALE DELLE RICERCHE (IT) | 1993-12-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10829501-B2 | Spiroheptane salicylamides and related compounds as inhibitors of ROCK | ROCK1, MYLK, RHOA | MEN1 353/4885LMNA 1180/4885KMT2A 1848/4885 |
| US-11339185-B2 | Cyclic dinucleotides as anticancer agents | DPYD, NTPCR, CD38 | MEN1 1800/4885LMNA 1855/4885KMT2A 2383/4885 |
| US-10611776-B2 | Spiroheptane salicylamides and related compounds as inhibitors of rock | ROCK1, MYLK, RHOA | MEN1 305/4885LMNA 1214/4885KMT2A 2037/4885 |
| US-20200131200-A1 | SPIROHEPTANE SALICYLAMIDES AND RELATED COMPOUNDS AS INHIBITORS OF ROCK | ROCK1, MYLK, RHOA | MEN1 353/4885LMNA 1180/4885KMT2A 1848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.